AAV-Mediated Clarin-1 Expression in the Mouse Retina: Implications for USH3A Gene Therapy
Fig 3
Evaluation of retinal function and CLRN1-HA expression following subretinal delivery.
A. Bar graphs show the average maximum ERG b-wave amplitudes in scotopic, dark-adapted conditions of untreated wild-type control eyes, compared to AAV-treated eyes that received decreasing doses of AAV-CLRN1-HA vector (2 months post-injection). Maximum b-wave amplitudes in AAV-treated eyes were dose dependent, and were significantly lower than untreated controls at 1010, 109, and 108 vg (*, p<0.05, **, p<0.001). B. Localization of CLRN1-HA protein following subretinal delivery of the AAV2quad smCBA vector. CLRN1-HA fluorescence (green) was detected by immunohistochemistry in photoreceptor IS region, ONL and OPL, and was absent from the outer segments (labelled with a rhodopsin antibody, red). The eyes received diluted vector (108 vg). Scale bar: 20 μm.